Sumitomo Mitsui Trust Group Inc. Has $13.05 Million Holdings in DaVita Inc. $DVA

Sumitomo Mitsui Trust Group Inc. cut its position in shares of DaVita Inc. (NYSE:DVA) by 13.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 98,222 shares of the company’s stock after selling 15,281 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.14% of DaVita worth $13,051,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. NewEdge Advisors LLC lifted its stake in DaVita by 20.8% in the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after acquiring an additional 88 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of DaVita by 19.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock valued at $27,403,000 after purchasing an additional 28,739 shares in the last quarter. Sovran Advisors LLC acquired a new stake in shares of DaVita in the 2nd quarter valued at $472,000. Wedge Capital Management L L P NC boosted its holdings in DaVita by 3.3% in the second quarter. Wedge Capital Management L L P NC now owns 268,444 shares of the company’s stock worth $38,240,000 after purchasing an additional 8,538 shares in the last quarter. Finally, Abacus FCF Advisors LLC acquired a new position in DaVita during the second quarter worth $5,632,000. Institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on DVA shares. Zacks Research raised DaVita from a “strong sell” rating to a “hold” rating in a research report on Friday, November 28th. Truist Financial decreased their target price on DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a research report on Monday, January 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. TD Cowen dropped their price target on shares of DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a research report on Monday, November 3rd. Finally, Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Monday, November 3rd. One research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, DaVita currently has a consensus rating of “Hold” and a consensus target price of $145.60.

DaVita Price Performance

NYSE DVA opened at $104.76 on Friday. The company’s fifty day moving average is $116.14 and its two-hundred day moving average is $127.70. The firm has a market capitalization of $7.40 billion, a price-to-earnings ratio of 10.79, a P/E/G ratio of 0.64 and a beta of 0.99. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $179.60.

DaVita (NYSE:DVA) last released its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). The firm had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.43 billion. DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period last year, the business earned $2.59 earnings per share. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.